A Phase 2 Study of Avutometinib and Defactinib in People With Thyroid Cancer


Full Title

Phase II of Avutometinib (VS-6766) and Defactinib In RAF Dimer-Driven RAI-Refractory Differentiated and Anaplastic Thyroid Cancer Patients


The purpose of this study is to see how well avutometinib and defactinib work in people with thyroid cancer. The people in this study have one of these kinds of cancer:

  • Differentiated thyroid cancer that keeps growing or spreads
  • Anaplastic thyroid cancer

In addition, they have cancer with a change (mutation or variant) in certain genes that can cause cancer cells to grow. This is called RAF dimer-driven disease.

By blocking proteins called kinases, avutometinib and defactinib may help slow or stop the growth of thyroid cancer. Researchers also want to see if the use of thyroid-stimulating hormone plus radioiodine may help people with differentiated thyroid cancer. Avutometinib and defactinib are both taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have differentiated thyroid cancer that keeps growing or spreads or have anaplastic thyroid cancer.
  • Have RAF dimer-driven disease.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information or to see if you can join this study, please call Dr. Alan Ho’s office at 646-608-3774.




Phase II (phase 2)

Disease Status

Relapsed or Refractory




ClinicalTrials.gov ID